Bli medlem
Bli medlem

Du är här

2016-10-26

Active Biotech: Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

Lund (Sweden) and Tel Aviv (Israel), 26 October 2016 -
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) and NeoTX Therapeutics Ltd.
announced today that they have entered into a licensing agreement for Active
Biotech's investigational compound Naptomumab estafenatox ("ANYARA") for
cancer immunotherapy. NeoTX will be responsible for the worldwide clinical
development and commercialization of the drug. This partnership is a key
milestone in NeoTX's strategy to bring tumor recognition enhancing
therapeutics to the market.

"We are very enthusiastic about our collaboration with Active Biotech. At
NeoTX, we are strongly committed to developing innovative immunotherapies for
unmet medical needs. "Active Biotech brings to our collaboration outstanding
scientific and intellectual capital, and a powerful commitment to positively
impact the treatment of cancer,"
saidAsher Nathan, Chief Executive Officer of NeoTX.
Dr. Marcel Rozencweig, Chief Medical Officer of NeoTX
and former Head of Global Clinical Oncology Research at BMS said"We are
looking forward to developing ANYARA for immuno-oncology applications.
We believe that the ANYARA technology is well suited to increase tumor
recognition by the immune system and has demonstrated synergistic activity in
combination with checkpoint inhibitors in animal models. As such, ANYARA
would be attractive in combination with checkpoint inhibitors whose efficacy
can be limited by poor tumor recognition".

"We are excited about the partnership with NeoTX, who we consider as an ideal
partner for ANYARA. This partnership constitutes the next step in the
clinical development, as well as the commercialization strategy, for the
project."
saidTomas Leanderson, President &CEO of Active Biotech.

About the agreement

Under the terms of the agreement, Active Biotech grants NeoTX exclusive rights
to develop and commercialize ANYARA worldwide in cancer indications. The
total deal value amounts to $71 million and is contingent upon achievement of
clinical, regulatory and commercial milestones whereof Active Biotech will
receive $250 000 as an initial payment upon signing. In addition, NeoTX will
pay Active Biotech progressive, double-digit royalties on its net sales.

About ANYARA

ANYARA is a TTS (Tumor Targeting Superantigen) compound that increases the
ability of the immune system to recognize the tumor. Synergy has been
reported in vivo with a combination of ANYARA and a checkpoint inhibitor in
an experimental tumor model. Clinically, the development of ANYARA has
primarily been focused on cancer indications with a high unmet medical need.
Positive data was reported from clinical Phase I trials in lung cancer, renal
cell cancer and pancreatic cancer, where ANYARA was studied both as a single
agent (monotherapy) and in combination with an established tumor therapy -
docetaxel (Taxotere®) - in patients with advanced cancer. The results showed
that ANYARA was well tolerated both as monotherapy and in combination with
docetaxel, and increased tumor recognition by T cells.

A Phase 2/3 trial of ANYARA in combination with interferon alpha in renal cell
cancer demonstrated acceptable safety but did not meet its primary efficacy
endpoint in the ITT population. The upcoming clinical trial will be done in
combination with drugs that inhibit checkpoint dampening of the immune
system, a combination strategy in line with the mode of action of ANYARA and
supported by preclinical data.

NeoTX Therapeutics Ltd.
is based in Rehovot Israel and is a clinical stage immuno-oncology company.
NeoTX was founded to bring safe and effective immunotherapies to cancer
patients. Please visit www.neotx.com for more information.

Active Biotech AB (publ)
(Nasdaq Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally
administered small molecule with unique immunomodulatory properties, is in
pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visitwww.activebiotech.comfor more information.

----------------------------------------------------------------------------
| For further information, please contact: NeoTX Therapeutics Ltd. |
| (Corp.Reg. No. 515220929) |
|Asher Nathan CEO 2 Pekeris Street |
|Tel: +1 609 718 2305 x 1 Rehovot, Israel |
| Tel: +1 609 718 2305 |
|Robert Harow, CFO Tel: +972 3 912 5853 |
|Tel: +1 609 718 2305 x 2 |
| Tomas Leanderson, President and CEO Active Biotech AB |
| |
|Tel: +46 46 19 20 95 (Corp. Reg. No. 556223-9227) |
| Box 724, SE-220 07 Lund, Sweden |
|Hans Kolam, CFO Tel: +46 46 19 20 00 |
|Tel: +46 46 19 20 44 |
----------------------------------------------------------------------------
This information is information that Active Biotech AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person set out
above, at 08.30 am CET on October 26, 2016.

20161026_Active Biotech_NeoTX_
http://hugin.info/1002/R/2050859/767387.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.